Inebilizumab Shows Lasting Protection Against NMOSD Attacks Regardless of Prior Immunosuppressant Use
A long-term analysis of the N-MOmentum trial shows inebilizumab reduces NMOSD attack risk and disability worsening equally well in patients ...
A long-term analysis of the N-MOmentum trial shows inebilizumab reduces NMOSD attack risk and disability worsening equally well in patients ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine